StockData
Akebia Therapeutics, Inc. logo

Akebia Therapeutics, Inc. (AKBA) income statement

AKBANasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$0.41+0.01 (+2.12%)

Close on Nov 18, 2026Market cap $113.31MP/E –Yield –

Akebia Therapeutics, Inc. income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin
79.6%
Operating margin
-6.9%
Net margin
-13.5%
Return on equity, FY2025
64.5%

Financial strength

Current ratio
1.43
Debt to equity
1.98
Debt to assets
14.2%
Cash to current liabilities
96.7%

Valuation

P/E ratio
–
Price to sales
0.52
Price to book
4.53
Dividend yield
–

See a number that looks wrong?